ANCA-associated glomerular injury may be mediated by ANCA binding to neutrophils/monocytes, resulting in enhanced neutrophil granule release and endothelial cell damage. Our experimental approach is based on the premise that ANCA are pathogenic and are responsible for mediating the most common forms of systemic necrotizing vasculitis and crescentic glomerulonephritis. The first Specific Aim focuses on the mechanism/s of ANCA-induced neutrophil/monocyte activation. The proposed in vitro and in vivo studies are complementary and will be done in parallel. The in vitro studies will examine the relative contribution of the F(ab')2 portion of the antibody versus the Fc portion, by treating cells from healthy individuals. We will engineer anti-PR3 and MPO F(ab')2- like molecules, with and without Fc regions to determine this. The in vivo studies will investigate changes in circulating cells from patients with active disease, in remission and at relapse, i.e., examine the surface expression ANCA antigens, and examine the changes in transcription of genes associated with inflammation. The second Specific Aim will test the effects of ANCA and its antigens, PR3 and MPO, on the endothelium. These studies will be done in parallels with Specific Aim 1. We known that PR3 and MPO are translocated into endothelial cells and PR3 induced apoptosis but MPO did not. We will determine the mechanism of cell entry and the effects on cell signaling pathways that lead to apoptosis. Be deletion analysis we will determine the domain of PR3 responsible for the pro-apoptotic activity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
3P01DK058335-03S1
Application #
6646633
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
$167,150
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
McCall, A Scott; Bhave, Gautam; Pedchenko, Vadim et al. (2018) Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes. J Am Soc Nephrol 29:2619-2625
Alba, Marco A; Jennette, J Charles; Falk, Ronald J (2018) Pathogenesis of ANCA-Associated Pulmonary Vasculitis. Semin Respir Crit Care Med 39:413-424
Weiner, Maria; Bjørneklett, Rune; Hrušková, Zdenka et al. (2018) Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant :
van Daalen, Emma E; Jennette, J Charles; McAdoo, Stephen P et al. (2018) Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. Clin J Am Soc Nephrol 13:63-72
Thorpe, Carolyn T; Thorpe, Joshua M; Jiang, Tao et al. (2018) Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis. Semin Arthritis Rheum 47:507-519
Alba, Marco A; Flores-Suárez, Luis Felipe; Henderson, Ashley G et al. (2017) Interstital lung disease in ANCA vasculitis. Autoimmun Rev 16:722-729
Cortazar, Frank B; Pendergraft 3rd, William F; Wenger, Julia et al. (2017) Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 69:1045-1053
Payan Schober, Fernanda; Jobson, Meghan A; Poulton, Caroline J et al. (2017) Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis. Am J Nephrol 45:248-256
Jones, Britta E; Yang, Jiajin; Muthigi, Akhil et al. (2017) Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. J Am Soc Nephrol 28:1175-1187
Merkel, Peter A; Xie, Gang; Monach, Paul A et al. (2017) Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol 69:1054-1066

Showing the most recent 10 out of 86 publications